1023 results about "Pharmacodynamics" patented technology

Compositions and methods for modulating the activity of RNA and DNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. Reactive portions which act, alternatively, through phosphorodiester bond cleavage, through backbone sugar bond cleavage or through base modification are preferrably employed. Groups which improve the pharmacodynamic and pharmacokinetic properties of the oligonucleotides are also useful in accordance with certain embodiments of this invention. Delivery of the reactive or non-reactive functionalities into the minor groove formed by the hybridization of the composition with the target RNA is also preferrably accomplished. Therapeutics, diagnostics and research methods and also disclosed. Synthetic nucleosides and nucleoside fragments are also provided useful for elaboration of oligonucleotides and oligonucleotide analogs for such purposes.

A pharmacodynamic (PD), pharmacokinetic (PK), or both and PK guided infusion device, system and method optimizes the safety and efficacy of various forms of treatment or therapy (e.g., drug and/or fluid) in a variety of health-care and other settings.

The present invention provides modified oligomeric compounds that modulate gene expression via an RNA interference pathway. The oligomeric compounds of the invention include one or more conjugate moieties that can modify or enhance the pharmacokinetic and phamacodynamic properties of the attached oligomeric compound.

The invention belongs to the field of medicine, and in particular relates to a medical application of 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-((3-chloro-4-methylphenyl) amino)-4-oxobutanoate in a selective histone lysine-specific demethylase 1 (LSD1) inhibitor, especially the application in anti-tumor medicaments. Pharmacodynamic tests indicate that the 2-([1,1'-biphenyl]-4-yl)-2-oxoethyl 4-((3-chloro-4-methylphenyl) amino)-4-oxobutanoate has a remarkable LSD1 inhibiting effect, and has selectivity to homologous proteins MAO-A (monoamine oxidase-A) and MAO-B.

Methods for treating Hepatitis infections are provided. In one embodiment, an initial dosage of interferon is administered to a patient, and interferon serum levels and viral load data is collected over time. This data can be used to determine patient-specific pharmacokinetic and pharmacodynamic parameters and then construct patient-specific interferon delivery profiles. Patient-specific delivery profiles can then be used to design patient-specific therapeutic regimens.

Disclosed are compositions and methods that provide pharmacodynamic effects specific to therapeutic macromolecules. The effects may result from reduced doses of therapeutic macromolecules in combination with immunosuppressant doses. The effects may also be enhanced with such compositions.

An orally taken medicine of hyproval-PA in the form of tablet, capsule, soft capsule, instant particles, etc for treating breast cancer and functional metrorrhagia is disclosed. its advantages are high biologic utilization rate and high curative effect.

Materials and methods are provided for producing aptamer therapeutics having improved pharmacokinetic and pharmacodymanic properties, as well as increased target valency. The aptamers produced by the methods of the invention are useful as therapeutics for treating disease.

A unit dosage form, such as a capsule or the like for delivering drugs into the body in a circadian release fashion, is comprising of one or more populations of propranolol-containing particles (beads, pellets, granules, etc.). Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release cardiovascular drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need during the day, i.e., mimicking the circadian rhythm and severity/manifestation of a cardiovascular disease, predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro/in vivo correlations.

The invention discloses a xiluomosi liposome freeze dried and making technique, which comprises the following steps: selecting liposome component, buffer, organic solvent, antioxidant and freeze-drying protective as raw material; adopting film diffusion method to make the liposome turbid liquor with xiluomosi through high-pressure or hypersonic dispersing method evenly; drying the liposome to improve the storage stability obviously; dispersing the freeze dried at random proportion in the water evenly without any sediment and impurity; making the packing rate of liposome at 96% with the grain size at 50-250nm; improving the drug effect greatly in comparison with oral agent; lengthening the circulating time in the blood; elevating the biological utility of drug.

The invention belongs to the fields of polymer chemistry and medicinal preparations, and particularly relates to a method for synthesizing an active targeted hyaluronic acid-polylactic acid carrier, a method for preparing an anti-tumor medicinal micelle of the active targeted hyaluronic acid-polylactic acid carrier and an application thereof. By adopting a novel self-assembly technology, amphipathic PEG (polyethylene glycol) block polyester copolymer and tumor targeted ligand hyaluronic acid-polylactic acid copolymer are self-assembled by means of the electrostatic interaction to form a multifunctional composite micelle; the solubility of insoluble tumor medicaments and the drug loading capacity and encapsulation efficiency of water-soluble anti-tumor medicines can be remarkably improved by virtue of the anti-cancer drug-loaded micelle and composite micelle composition, the medicines can be biodegraded in a body, phagocytosis of a reticuloendothelial system (RES) and excretion of a kidney can be avoided. The active targeted hyaluronic acid-polylactic acid carrier has a long-circulating effect, the multifunctional composition has a prominent advantage of tumor active targeting effect, and parameters of pharmacodynamics in vitro and in vivo of the micelle are remarkably superior to those of common anti-tumor injections. Clinically acceptable administration means of the micelle includes injection administration or mucosal administration, and preparations of the micelle can be injection, transfusion, injection lyophilized powder injections or dry powder inhalation.

The invention discloses caper extract and a preparation method thereof. The method comprises the following steps: medicinal materials are crushed, decocted in water or subjected to heating reflux extraction by utilization of ethanol with different concentrations, and added with the ethanol for impurity precipitation after concentration of extract; supernatant or more than 80 percent ethanol extract is subjected to concentration at reduced pressure; extract 1 is obtained after recovery of the ethanol, dried and dissolved in water, subjected to deesterification by utilization of petroleum ether, and extracted by ethyl acetate; an extracted position and a water-soluble position of the ethyl acetate are subjected to vacuum concentration and drying respectively and prepared into extract 2 and extract 3 respectively; the extract 1 contains 30 compounds including 5 novel compounds such as caper alkali A, and so on; the extract 2 contains 18 compounds such as a para hydroxybenzoic acid, and so on ; and the extract 3 contains 18 compounds including 5 novel compounds such as the caper alkali A, and so on. As proved by pharmacodynamic experiments, the extract 1, the extract 2 and the extract 3 have analgesic and anti-inflammatory activity, and can be used for preparing medicines for treating rheumatic arthritis, rheumatoid inflammation or scapulohumeral periarthritis.

The invention relates to the field of pharmaceutical chemistry, particularly a group of amide compounds (I) and a preparation method therefor and use thereof. Pharmacodynamic experiments prove that the compounds of the invention can be used for preparing medicines for treating leukemia. The formula (I) is shown in the description.

The invention relates to a broomrape extract, broomrape total glycoside and broomrape polysaccharide, which are prepared by adopting water or methanol or ethanol as an extracting solvent and by means of decoction, reflux, diacolation, immersion or supersound. The broomrape extract and the broomrape total glycoside are subjected to further pharmacodynamic experiments such as oxidation resistance, fatigue resistance, senile dementia resistance and hepatitis resistance; the application of the broomrape extract, the broomrape total glycoside and the broomrape polysaccharide in the aspect of preventing and treating diseases is elaborated; and a novel approach and novel application are provided for further utilization of broomrape plants.

A method of performing interactive clinical trials for testing a new drug comprising performing a pre-clinical phase in which a computer model for pharmacokinetics and pharmacodynamics of the drug is created and adjusted based on in vitro studies and in vivo studies in animals. A phase I clinical research is performed in which a clinical trial on at least a single dose is performed in parallel with performing computer simulation studies using the computer model. The computer model is adjusted based on comparison of the results of the clinical research and the computer simulation. A maximal tolerated dose, minimum effective dose, and a recommended dose is determined based on the phase I clinical research in conjunction with the computer simulations. The drug is checked for cumulative effects and providing this information to the computer model. Multiple simulations are performed using the computer model with different doses and dosing intervals. An optimal protocol is determined for the most responsive patient populations and indications for a phase II clinical trial. Phase II clinical trial is performed where a number of small scale clinical trials are performed in parallel based on results of the above. The interim results are analyzed to choose the most promising regimens for continued clinical trials. Phase III clinical research is performed for chosen indications by chosen protocols. Phase IV studies are performed for post-marketing subpopulation analysis and long term product safety assessment.

The invention discloses an mRNA nucleic acid drug delivery system, a preparation method and application. The system comprises lipid nanoparticles used for loading one or more mRNAs, and the lipid nanoparticles are prepared from raw materials including ionizable cationic lipid, phospholipid auxiliary lipid, cholesterol and phospholipid polyethylene glycol derivatives. According to the non-viral-vector mRNA nucleic acid drug targeting intracellular delivery system, mRNA is concentrated and loaded through the electrostatic interaction of ionizable cationic lipid and the mRNA, the phospholipid auxiliary lipid component-mediated pH sensitivity and advanced inclusion escape can enable an mRNA nucleic acid drug to be efficiently delivered to target cells, and the mRNA nucleic acid drug is released to cytoplasm of the target cells to play a pharmacodynamic role. The phospholipid auxiliary lipid increases the advanced inclusion escape ability of the mRNA/lipid nanoparticles, and increases the stability of the mRNA/lipid nanoparticles and the mRNA transfection efficiency. The system has efficient and stable mRNA drug intracellular delivery efficiency, and significantly improves the prevention and treatment effects of mRNA nucleic acid drugs.

The invention discloses a taxol phospholipids compound, a medicine composition and application thereof. The medicine composition comprises the taxol phospholipids compound or a combined medicine composition which is combined by the taxol phospholipids compound and a carrier which can be accepted in pharmacology, namely a liquid preparation, a solid preparation, a semi-solid preparation, a capsule, a granule, a gel and an injection. The medicine composition is the taxol phospholipids compound or a liposomal nano particle which is prepared by the taxol phospholipids compound and an assistant, and the diameter of the particle is 10 to 1000 nanometer. The taxol phospholipids compound and the liposomal nano particle can be used as liquid preparations, solid preparations, semi-solid preparations, sterilization preparations and sterile preparations, the toxicity is low, so that the taxol phospholipids compound and the liposomal nano particle can be applied to the efficient treatment of various tumors.

The invention relates to a traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases, mainly containing one or more of Salvia miltiorrhiza, folium ginkgo, panax notoginseng, kudzuvine root Pueraria lobata, rhizoma ligustici wallichii, hawthorn and lotus leaf. The preparation method comprises the steps of selecting one or more of the Salvia miltiorrhiza, the folium ginkgo, the panax notoginseng, the kudzuvine root Pueraria lobata, the rhizoma ligustici wallichii and the hawthorn and lotus leaf, decocting, extracting active ingredients and concentrating the extracting solution to a certain concentration to obtain the Chinese traditional medicine preparation. In addition, the concentrated solution can be further made into capsules, tablets, granules, oral liquid, pills, pulvis, injection and sustained and controlled release preparations. Toxicologic and pharmacologic agent experiments show that the invention has no toxic side effect, is safe to use, has the functions of promoting blood circulation, remove blood stasis, reducing fat, freeing channels and eliminating phlegm and is suitable for phlegm stasis internal-block type cardiovascular and cerebrovascular diseases.